Granted Patent
B2
US 12,508,306 · App. 17/050,318 · Granted Dec 30, 2025
Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
Inventors:
Brian J. Debosch (St. Louis, MO); Cassandra Higgins (St. Louis, MO); Yiming Zhang (St. Louis, MO); Allyson Mayer (St. Louis, MO)
Assignee:
Washington University
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to compositions and methods of using the same for the treatment of various metabolic diseases and related disorders (e.g. diabetes mellitus, NAFLD, obesity, metabolic syndrome). The compositions and methods of the disclosure relate to the administration of an arginine-degrading enzyme.
Claims (11)
1 . A method for treating a metabolic disease selected from the group consisting of hepatic steatosis, hepatic inflammation, insulin resistance, and adiposity in a human subject in need thereof comprising administering to the subject a composition comprising a therapeutically effective amount of an Adeno-associated virus serotype 8 (AAV8) vector comprising a nucleic acid sequence encoding an arginase II.
2 . The method of claim 1 , wherein the AAV8 vector has a genome comprising open reading frames that encode the arginase II.
3 . The method of claim 2 , wherein nucleic acid sequence encodinq the arginase II, is operably linked to a liver-specific promoter.
4 . The method of claim 1 , wherein the nucleic acid sequence encoding arginase II encodes a polypeptide comprising the sequence set forth in SEQ ID NO: 2.
5 . The method of claim 4 , wherein the arginase II is further modified by coupling with proteins or peptides, wherein one or more proteins or peptides are directly or indirectly linked to the arginase II.
6 . The method of claim 5 , wherein the one or more proteins or peptides is selected from the group consisting of thyroxine-binding protein, transthyretin, a1-acid glycoprotein, transferrin, fibrinogen, immunoglobulin, Ig Fc, albumin, and fragments thereof.
7 . The method of claim 4 , wherein the arginase II is further modified by covalent attachment with polyethylene glycol (PEG).
8 . The method of claim 7 , wherein the PEG has a total weight average molecular weight of 1,000 to 50,000 daltons; from 3,000 to 40,000 daltons; from 5,000 to 30,000 daltons; from 8,000 to 30,000 daltons; from 11,000 to 30,000 daltons; from 12,000 to 28,000 daltons; from 16,000 to 24,000 daltons; from 18,000 to 22,000 daltons; or from 19,000 to 21,000 daltons.
9 . The method of claim 8 , wherein the PEG has a total weight average molecular weight of 20,000 daltons.
10 . The method of claim 7 , wherein the PEG is a branched or straight chain.
11 . The method of claim 1 , wherein the subject has decreased fat mass relative to the subject prior to administration of the arginine II.
Assignments (2)
CONFIRMATORY LICENSE
Recorded Dec 15, 2020
From: WASHINGTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 054759/0250 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 11, 2020
From: DEBOSCH, BRIAN J.; HIGGINS, CASSANDRA; ZHANG, YIMING; MAYER, ALLYSON
To: WASHINGTON UNIVERSITY
Reel/Frame 054337/0512 →
Continuity (2)
Provisional Application
62662564
· Apr 25, 2018
References Cited (199)
US 4241046A
· Papahadjopoulos et al.
· 1980
[cited by applicant]
US 4394448A
· Szoka, Jr. et al.
· 1983
[cited by applicant]
US 4529561A
· Hunt et al.
· 1985
[cited by applicant]
US 4554101A
· Hopp
· 1985
[cited by applicant]
US 4755388A
· Heath et al.
· 1988
[cited by applicant]
US 4797368A
· Carter et al.
· 1989
[cited by applicant]
US 4828837A
· Uster et al.
· 1989
[cited by applicant]
US 4868116A
· Morgan et al.
· 1989
[cited by applicant]
US 4897355A
· Eppstein et al.
· 1990
[cited by applicant]
US 4925661A
· Huang
· 1990
[cited by applicant]
US 4954345A
· Muller
· 1990
[cited by applicant]
US 4957735A
· Huang
· 1990
[cited by applicant]
US 4980286A
· Morgan et al.
· 1990
[cited by applicant]
US 5043164A
· Huang et al.
· 1991
[cited by applicant]
US 5064655A
· Uster et al.
· 1991
[cited by applicant]
US 5077211A
· Yarosh
· 1991
[cited by applicant]
US 5196195A
· Griffith
· 1993
[cited by examiner]
US 5264618A
· Felgner et al.
· 1993
[cited by applicant]
US 6342390B1
· Wiener et al.
· 2002
[cited by applicant]
US 6723551B2
· Kotin et al.
· 2004
[cited by applicant]
US 6821511B2
· Kotin et al.
· 2004
[cited by applicant]
US 7319011B2
· Riggins et al.
· 2008
[cited by applicant]
US 9255262B2
· Wong et al.
· 2016
[cited by applicant]
US 9333268B2
· Bomalaski et al.
· 2016
[cited by applicant]
US 20030017146A1
· Slobodan et al.
· 2003
[cited by applicant]
WO 1989007136A2
· 1989
[cited by applicant]
WO 1990002806A1
· 1990
[cited by applicant]
WO 2006114691A1
· 2006
[cited by applicant]
WO 2010051533A2
· 2010
[cited by applicant]
WO 2012061015A2
· 2010
[cited by applicant]
WO 2014089212A1
· 2014
[cited by applicant]
WO 2017109706A1
· 2017
[cited by applicant]
WO 2018032020A1
· 2018
[cited by applicant]
WO 2018085551A2
· 2018
[cited by applicant]
WO 2019228510A1
· 2019
[cited by applicant]
WO 2020009740A2
· 2020
[cited by applicant]
Hu et al., Am. Soc. Gene Cell Ther., 22(10):1792-1802 (2014) (Year: 2014).
[cited by examiner]
Hu et al., Curr. Protein Peptide Sci., 18:599-608 (2017) (Year: 2017).
[cited by examiner]
Johnson et al., Obesity, 23(2):383-390 (2015) (Year: 2015).
[cited by examiner]
Spolarics et al., Arch. Biochem. Biophys., 274(2):426-433 (1989) (Year: 1989).
[cited by examiner]
Wu et al., (Amino Acids, 37:153-168 (2009) (Year: 2009).
[cited by examiner]
Accession No. A0A024R6A0_HUMAN (2014) (Year: 2014).
[cited by examiner]
Gonzalez-Muniesa, P. et al., “Obesity,” Nat. Rev. Dis. Primers, Jun. 2017, pp. 1-18, vol. 3, Article No. 17034.
[cited by applicant]
Helene, C. et al., “Control of Gene Expression by Triple Helix-Forming Oligonucleotides. The Antigene Strategy,” Ann. N.Y. Acad. Sci., Oct. 1992, pp. 27-36, vol. 660, No. 1.
[cited by applicant]
Higgins, C. et al., “Hepatocyte ALOXE3 is induced during adaptive fasting and enhances insulin sensitivity by activating hepatic PPARgamma,” JCI Insight, 2018, pp. 1-18, vol. 3, No. 16, e120794.
[cited by applicant]
Honka, M-J. et al., “Insulin-stimulated glucose uptake in skeletal muscle, adipose tissue and liver: a positron emission tomography study,” Eur. J. Endocrinol., 2018, pp. 523-531, vol. 178, No. 5.
[cited by applicant]
Huang, J. et al., “Feeding and fasting controls liver expression of a regulator of G protein signaling (Rgs16) in periportal hepatocytes,” Comp. Hepatol., 2006, pp. 1-11, vol. 5, No. 8.
[cited by applicant]
Im, D-S. et al., “The AAV Origin Binding Protein Rep68 Is an ATP-Dependent Site-Specific Endonuclease with DNA Helicase Activity,” Cell, May 1990, pp. 447-457, vol. 61, No. 3.
[cited by applicant]
Inagaki, T. et al., “Endocrine Regulation of the Fasting Response by PPARalpha-Mediated Induction of Fibroblast Growth Factor 21,” Cell Metab., Jun. 2007, pp. 415-425, vol. 5, No. 6.
[cited by applicant]
International Search Report and Written Opinion dated Mar. 24, 2020 from related Patent Application No. PCT/US2019/029205; 16 pgs.
[cited by applicant]
Irabarren, C. et al., “Metabolic Syndrome and Early-Onset Coronary Artery Disease” Is the Whole Greater Than Its Parts?, J. Am. Coll. Cardiol., Nov. 2006, pp. 1800-1807, vol. 48, No. 9.
[cited by applicant]
Kang, H. et al., “Early- and Late-onset Complications of the Ketogenic Diet for Intractable Epilepsy,” Epilepsia, 2004, pp. 1116-1123, vol. 45, No. 9.
[cited by applicant]
Karlin, S. et al., “Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes,” PNAS, Mar. 1990, 2264-2268, vol. 87.
[cited by applicant]
Klonoff, D. et al., “Drugs in the Pipeline for the Obesity Market,” J. Diabetes. Sci. Technol., Sep. 2008, pp. 913-918, vol. 2, No. 5.
[cited by applicant]
Kosinski, C. et al., “Effects of Ketogenic Diets on Cardiovascular Risk Factors: Evidence from Animal and Human Studies,” Nutrients, 2017, pp. 1-16, vol. 9, No. 517.
[cited by applicant]
Kremer, J. et al., “Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers,” Cell Reports, Jan. 2017, pp. 991-1004, vol. 18.
[cited by applicant]
Kyte, J. et al., “A Simple Method for Displaying the Hydropathic Character of a Protein,” J. Mol. Biol., 1982, pp. 105-132, vol. 157.
[cited by applicant]
Lee, J. et al., “Aptamer therapeutics advance,” Curr. Opin. Chem. Biol., Jun. 2006, pp. 282-289, vol. 10, No. 3.
[cited by applicant]
Lee, E. et al., “Long-term Survival of the Juvenile Lethal Arginase-deficient Mouse With AAV Gene Therapy,” Mol. Ther., Oct. 2012, pp. 1844-1851, vol. 20, No. 10.
[cited by applicant]
Link, A. et al., “Beyond toothpicks: new methods for isolating mutant bacteria,” Nat. Rev. Microbiol., Sep. 2007, pp. 680-688, vol. 5, No. 9.
[cited by applicant]
Liu, C et al., “Targeting arginase-II protects mice from high-fat-diet-induced hepatic steatosis through suppression of macrophage inflammation,” Sci. Rep., 2016, pp. 1-13, vol. 6, No. 20405.
[cited by applicant]
Longo, V. et al., “Fasting: Molecular Mechanisms and Clinical Applications,” Cell Metab., Feb. 2014, pp. 181-192, vol. 19, No. 2.
[cited by applicant]
Lozzo, P. et al., “Insulin-Mediated Hepatic Glucose Uptake Is Impaired in Type 2 Diabetes: Evidence for a Relationship with Glycemic Control,” J. Clin. Endocrinol. Metab., May 2003, pp. 2055-2060, vol. 88, No. 5.
[cited by applicant]
Maher, L., “DNA Triple-Helix Formation: An Approach to Artificial Gene Repressors?,” BioEssays, Dec. 1992, pp. 807-815, vol. 14, No. 12.
[cited by applicant]
Malik, S. et al., “Impact of the Metabolic Syndrome on Mortality From Coronary Artery Disease, Cardiovascular Disease, and All Causes in United States Adults,” Circulation, 2004, pp. 1245-1250, vol. 110.
[cited by applicant]
Mao, Y. et al., “Persistent Suppression of Ocular Neovascularization with Intravitreal Administration of AAVrh. 10 Coding for Bevacizumab,” Hum. Gene Therapy, Dec. 2011, pp. 1525-1535, vol. 22.
[cited by applicant]
Mardones, P. et al., “Mystery solved: Trehalose kickstarts autophagy by blocking glucose transport,” Sci. Signal., Feb. 2016, pp. 1-3, vol. 9, No. 416, fs2.
[cited by applicant]
Markan, K. et al., “Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding,” Diabetes, Dec. 2014, pp. 4057-4063, vol. 63, No. 12.
[cited by applicant]
Martin, B. et al., “Caloric restriction and intermittent fasting: Two potential diets for successful brain aging,” NIH Public Access Author Manuscript, Jan. 2009, pp. 1-21, published in final form as: Ageing Res. Rev., …
[cited by applicant]
Masri, S. et al., “Partitioning Circadian Transcription by SIRT6 Leads to Segregated Control of Cellular Metabolism,” Cell, Jul. 2014, pp. 659-672, vol. 158, No. 3.
[cited by applicant]
Mattson, M. et al., “Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems,” J. Nutr. Biochem., 2005, pp. 129-137, vol. 16.
[cited by applicant]
Mauldin, J. et al., “Recombinant Human Arginase Toxicity in Mice Is Reduced by Citrulline Supplementation,” Translat. Oncol., Feb. 2012, pp. 26-31, vol. 5, No. 1.
[cited by applicant]
Mayer, A. et al., “SLC2A8 (GLUT8) is a mammalian trehalose transporter required for trehalose-induced autophagy,” Sci. Rep., 2016, pp. 1-15, vol. 6, No. 38586.
[cited by applicant]
Mayer, A. et al., “Enhanced Hepatic PPARalpha Activity Links GLUT8 Deficiency to Augmented Peripheral Fasting Responses in Male Mice,” Endocrinology, May 2018, pp. 2110-2126, vol. 159, No. 5.
[cited by applicant]
Mcauley, K. et al., “Intensive Lifestyle Changes Are Necessary to Improve Insulin Sensitivity,” Diabetes Care, Mar. 2002, pp. 445-452, vol. 25, No. 3.
[cited by applicant]
Mehta, S. et al., “Non-invasive means of measuring hepatic fat content,” World J. Gastroenterol., Jun. 2008, pp. 3476-3483, vol. 14, No. 22.
[cited by applicant]
Ming, X-F. et al., “Arginase II Promotes Macrophage Inflammatory Responses Through Mitochondrial Reactive Oxygen Species, Contributing to Insulin Resistance and Atherogenesis,” Am. Heart J., Jul. 2012, pp. 1-18, vol. 1,…
[cited by applicant]
Moon, J. et al., “Arginase Inhibition Ameliorates Hepatic Metabolic Abnormalities in Obese Mice,” Plos One, Jul. 2014, pp. 1-10, vol. 9, No. 7.
[cited by applicant]
Morris, S. et al., “Human type II arginase: sequence analysis and tissue-specific expression,” Gene, 1997, pp. 157-161, vol. 193.
[cited by applicant]
Morris, S., “Enzymes of Arginine Metabolism,” J. Nutr., Oct. 2004, pp. 2743S-2747S, vol. 134, No. 10.
[cited by applicant]
Morris, S., “Arginine Metabolism: Boundaries of Our Knowledge,” J. Nutr., Jun. 2007, pp. 1602S-1609S, vol. 137, No. 6.
[cited by applicant]
Morris, S., “Arginine Metabolism Revisited,” J. Nutr., Dec. 2016, pp. 2579S-2586S, vol. 146, No. 12.
[cited by applicant]
Mulligan, R., “The Basic Science of Gene Therapy,” Sci., May 1993, pp. 926-932, vol. 260, No. 5110.
[cited by applicant]
Nakamura, M. et al., “Regulation of energy metabolism by long-chain fatty acids,” Prog. Lipid. Res., 2014, pp. 124-144, vol. 53.
[cited by applicant]
Navarro, L. et al., “Arginase 2 Deficiency Results in Spontaneous Steatohepatitis: A Novel Link Between Innate Immune Activation and Hepatic De Novo Lipogenesis,” HHS Public Access Author Manuscript, Feb. 2016, pp. 1-21…
[cited by applicant]
O'Neill, M. et al., “Tailoring Trehalose for Biomedical and Biotechnological Applications,” HHS Public Access Author Manuscript, Dec. 2017, pp. 1-42, published in final edited form as: Pure Appl. Chem., Sep. 2017, pp. 1…
[cited by applicant]
Park, Y. et al., “Pharmacology of
[cited by applicant]
Pashkov, V. et al., “Regulator of G Protein Signaling (RGS16) Inhibits Hepatic Fatty Acid Oxidation in a Carbohydrate Response Element-binding Protein (ChREBP)-dependent Manner,” J. Biol. Chem., Apr. 2011, pp. 15116-151…
[cited by applicant]
Pastore, N. et al., “TFE3 regulates whole-body energy metabolism in cooperation with TFEB,” EMBO Mol. Med., 2017, pp. 605-621, vol. 9, No. 5.
[cited by applicant]
Patterson, R. et al., “Intermittent Fasting and Human Metabolic Health,” HHS Public Access Author Manuscript, Aug. 2016, pp. 1-19, published in final edited form as: J. Acad. Nutr. Diet., Aug. 2015, pp. 1203-1212, vol. …
[cited by applicant]
Pereira, D. et al., “The Adeno-Associated Virus (AAV) Rep Protein Acts as both a Repressor and an Activator to Regulate AAV Transcription during a Productive Infection,” J. Virol., Feb. 1997, pp. 1079-1088, vol. 71, No.…
[cited by applicant]
Pernow, J. et al., “Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?,” Cardiovasc. Res., Jun. 2013, pp. 334-343, vol. 98, No. 3.
[cited by applicant]
Yang, Z. et al., “Functions of arginase isoforms in macrophage inflammatory responses: impact on cardiovascular diseases and metabolic disorders,” Front. Immunol., Oct. 2014, pp. 1-10, vol. 5, No. 533.
[cited by applicant]
Zhang, Y. et al., “TFEB-dependent induction of thermogenesis by the hepatocyte SLC2A inhibitor trehalose,” Autophagy, 2018, pp. 1959-1975, vol. 14, No. 11.
[cited by applicant]
Zhang, Y. et al., “Hepatic Arginase 2 (Arg2) is sufficient to convey the therapeutic metabolic effects of fasting,” Nat. Commun., 2019, pp. 1-16, vol. 10, No. 1587.
[cited by applicant]
Dillon, C. et al., “Rnai as an Experimental and Therapeutic Tool to Study and Regulate Physiological and Disease Processes,” Annu. Rev. Physiol., 2005, pp. 147-173, vol. 67.
[cited by applicant]
Perozich, J. et al., “Roles of conserved residues in the arginase family,” Biochim. Biophys. Acta., 1998, pp. 23-37, vol. 1382.
[cited by applicant]
Potthoff, M. et al., “Endocrine fibroblast growth factors 15/19 and 21: from feast to famine,” Genes Dev., 2012, pp. 312-324, vol. 26.
[cited by applicant]
Potthoff, M. et al., “Head Over Hepatocytes for FGF21,” Diabetes, Dec. 2014, pp. 4013-4015, vol. 63.
[cited by applicant]
Potthoff, M., “FGF21 and Metabolic Disease in 2016: A new frontier in FGF21 biology,” Nat. Rev. Endocrinol., 2017, pp. 74-76, vol. 13.
[cited by applicant]
Prinsen, H. et al., “Rapid quantification of underivatized amino acids in plasma by hydrophilic interaction liquid chromatography (HILIC) coupled with tandem mass-spectrometry,” J. Inherit. Metab. Dis., 2016, pp. 651-66…
[cited by applicant]
Pushparaj, P. et al., “Short Intefering RNA (SiRNA) as a Novel Therapeutic,” Clin. Exp. Pharmacol. Physiol., 2006, pp. 504-510, vol. 33.
[cited by applicant]
Reynolds, A. et al., “Rational siRNA design for RNA interference,” Nat. Biotechnol., Mar. 2004, pp. 326-330, vol. 22, No. 3, Nature Publishing Group.
[cited by applicant]
Rutledge, E. et al., “Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2,” J. Virol., Jan. 1998, pp. 309-319, vol. 72, No. 1.
[cited by applicant]
Sagner, G. et al., “Rapid filter assay for the detection of DNA polymerase activity: direct identification of the gene for the DNA polymerase from Thermus aquaticus,” Gene, 1991, pp. 119-123, vol. 97, No. 1.
[cited by applicant]
Sands, M, “AAV-Mediated Liver-Directed Gene Therapy,” Methods Mol. Biol., 2011, pp. 141-157, vol. 807, Chapter 6.
[cited by applicant]
Srivastava, A. et al., “Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome,” J. Virol., Feb. 1983, pp. 555-564, vol. 45, No. 2.
[cited by applicant]
Steriade, C. et al., “Mitochondrial Encephalopathy With Lactic Acidosis and Stroke-like Episodes (MELAS) May Respond to Adjunctive Ketogenic Diet,” Pediatr. Neurol., 2014, pp. 498-502, vol. 50.
[cited by applicant]
Stim, K. et al., “Nucleotide Sequence of the adi Gene, Which Encodes the Biodegradative Acid-Induced Arginine Decarboxylase of
[cited by applicant]
Studier, W., “Protein production by auto-induction in high-density cultures,” Protein Expr. Purif., 2005, pp. 207-234, vol. 41.
[cited by applicant]
Sutherland, J. et al., “The Metabolic Syndrome and Inflammation,” Metabol. Syndrome Related Dis., 2004, pp. 32-104, vol. 2, No. 2.
[cited by applicant]
Turner, R. et al., “Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin Patients With Type 2 Diabetes Mellitus,” JAMA, 1999, pp. 2005-2012, vol. 281.
[cited by applicant]
UniParc UPI0003C84481 (UniProtKB A0A6I9I2I0),
[cited by applicant]
UniProtKB O08691, Arginase-2, mitochondrial, mouse, Nov. 1, 1997; 10 pgs.
[cited by applicant]
UniProtKB 008701, Arginase-2 mitochondrial, rat, Jul. 15, 1998; 10 pgs.
[cited by applicant]
UniProtKB A0A2R9CNG5, Arginase,
[cited by applicant]
UniProtKB A0A2U3W017, Arginase,
[cited by applicant]
UniProtKB A0A2U3Y4M4, Arginase,
[cited by applicant]
UniProtKB A0A3Q7PYX4, Arginase,
[cited by applicant]
UniProtKB F1P658,
[cited by applicant]
UniProtKB F1SA26,
[cited by applicant]
UniProtKB F6Y7C7,
[cited by applicant]
UniProtKB G1LUN3,
[cited by applicant]
UniProtKB G1QJ08,
[cited by applicant]
UniProtKB G3MWN1,
[cited by applicant]
UniProtKB G3QS73, Gorilla gorilla gorilla (Western lowland gorilla), Nov. 16, 2011; 7 pgs.
[cited by applicant]
UniProtKB G3RRLO, Gorilla gorilla gorilla (Western lowland gorilla), Nov. 16, 2011.
[cited by applicant]
UniProtKB G3SNF5,
[cited by applicant]
UniProtKB H0XAI3,
[cited by applicant]
UniProtKB H2Q8H7,
[cited by applicant]
UniProtKB H2QTR0,
[cited by applicant]
UniProtKB K9KFW6,
[cited by applicant]
UniProtKB L5JMT6,
[cited by applicant]
UniProtKB L5KEB5,
[cited by applicant]
UniProtKB P05089,
[cited by applicant]
UniProtKB P07824,
[cited by applicant]
UniProtKB P78540,
[cited by applicant]
UniProtKB Q61176,
[cited by applicant]
UniProtKB R0JPH7,
[cited by applicant]
Verma, I., “Retroviral Vectors for Gene Transfer,” In Microbiology, Amer. Soc. for Microbiology, 1985, pp. 229-232.
[cited by applicant]
Walmagh, M. et al., “Trehalose Analogues: Latest Insights in Properties and Biocatalytic Production,” Int. J. Mol. Sci., 2015, pp. 13729-13745, vol. 16.
[cited by applicant]
Watanabe, M. et al., “AAVrh. 10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors,” Gene Ther., 2010, pp. 1042-1051, vol. 17.
[cited by applicant]
Wolff, J. et al., “Direct Gene Transfer into Mouse Muscle in Vivo,” Sci., Mar. 1990, pp. 1465-1468, vol. 247, No. 1949.
[cited by applicant]
Wu, P. et al., “Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism,” J. Virol., Sep. 2000, pp. 8635-8647, vol. 74, No. 18.
[cited by applicant]
Wu, Z. et al., “Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy,” Mol. Ther., Sep. 2006, pp. 316-327, vol. 14, No. 3.
[cited by applicant]
Xiong, Y. et al., “ARG2 impairs endothelial autophagy through regulation of MTOR and PRKAA/AMPK signaling in advanced atherosclerosis,” Autophagy, Dec. 2014, pp. 2223-2238, vol. 10, No. 12.
[cited by applicant]
Acsadi, G. et al., “Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs,” Nature, Aug. 1991, pp. 815-818, vol. 352.
[cited by applicant]
Ahmet, I. et al., “Cardioprotection by Intermittent Fasting in Rats,” Circulation, Nov. 2005, pp. 3115-3121, vol. 112.
[cited by applicant]
Aleman, G. et al., “Increase in FGF21 Stimulates Browning Markers in White Adipose Tissue in Rats Fed a Low Protein High Carbohydrate Diet During Acute Cold Exposure,” FASEB J., Apr. 2017, p. 652.12, vol. 31, No. S1.
[cited by applicant]
Altschul, S. et al., “Basic Local Alignment Search Tool,” J. Mo. Biol., 1990, pp. 403-410, vol. 215.
[cited by applicant]
Altschul, S. et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucl. Acid Res., 1997, pp. 3389-3402, vol. 25, No. 17.
[cited by applicant]
Angulo, P. et al., “Non-alcoholic fatty liver disease,” J. Gastroenterol. Hepatol., 2002, pp. S186-S190, vol. 17.
[cited by applicant]
Badman, M. et al., “Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARalpha and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States,” Cell Metab., Jun. 2007, pp. 426-437, vol. 5.
[cited by applicant]
Bailey, C. et al., “The UK Prospective Diabetes Study,” UK Prospective Diabetes Study (UKPDS) Group, Lancet, Dec. 1998, p. 1932, vol. 352.
[cited by applicant]
Bantel-Schaal, U. et al., “Human Adeno-Associated Virus Type 5 Is Only Distantly Related to Other Known Primate Helper-Dependent Parvoviruses,” J. Virol., 1999, pp. 939-947, vol. 73, No. 2.
[cited by applicant]
Barba, et al., WHO Expert Consultation, “Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies,” The Lancet, Jan. 2004, pp. 157-162, vol. 363, No. 9403.
[cited by applicant]
Barnosky, A. et al., “Intermittent fasting vs daily calorie restriction for type 2 diabetes prevention: a review of human findings,” Transl. Res., Oct. 2014, pp. 302-311, vol. 164, No. 4.
[cited by applicant]
Bassily, R. et al., “An improved synthesis of 4-azido-4-deoxy- and 4-amino-4-deoxy-alpha, alpha-trehalose and their epimers,” Carbohydr. Res., Feb. 1993, pp. 197-207, vol. 239.
[cited by applicant]
Bays, H., “Current and Investigational Antiobesity Agents and Obesity Therapeutic Treatment Targets,” Obes. Res., Aug. 2004, pp. 1197-1211, vol. 12, No. 8.
[cited by applicant]
Blethen, S. et al., “Arginine Decarboxylase from
[cited by applicant]
Boeker, E. et al., “Arginine Decarboxylase from
[cited by applicant]
Bonora, E. et al., “Increased risk of cardiovascular disease and chronic kidney disease in NAFLD,” Nat. Rev. Gastroenterol. Hepatol., 2012, pp. 372-381, vol. 9.
[cited by applicant]
Bordone, L. et al., “SIRT1 transgenic mice show phenotypes resembling calorie restriction,” Aging Cell, 2007, pp. 759-767, vol. 6.
[cited by applicant]
Brigham, K. et al., “Expression of a Prokaryotic Gene in Cultured Lung Endothelial Cells after Lipofection with a Plasmid Vector,” Am. J. Respir. Cell. Mol. Biol., 1989, pp. 95-100, vol. 1, No. 2.
[cited by applicant]
Caldwell, R. et al., “Arginase: an old enzyme with new tricks,” HHS Public Access Author Manuscript, Jun. 2016, pp. 1-26, published in final edited form as: Trends Pharmacol. Sci., Jun. 2015, pp. 395-405, vol. 36, No. 6.
[cited by applicant]
Caldwell, R. et al., “Arginase: a Multifaceted Enzyme Important in Health and Disease,” Physiol. Rev., Feb. 2018, pp. 641-665, vol. 98.
[cited by applicant]
Carter, B., “Adeno-Associated Virus Vectors in Clinical Trials,” Hum. Gene Ther., May 2005, pp. 541-550, vol. 16.
[cited by applicant]
Cearley, C. et al., “Transduction Characteristics of Adeno-associated Virus Vectors Expressing Cap Serotypes 7, 8, 9, and Rh10 in the Mouse Brain,” Mol. Ther., Mar. 2006, pp. 528-537, vol. 13, No. 3.
[cited by applicant]
Cederbaum, S. et al., “Arginases I and II: do their functions overlap?,” Mol. Genet. Metab., 2004, pp. S38-S44, vol. 81.
[cited by applicant]
Chalasani, N. et al., “The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, America…
[cited by applicant]
Charlton, M. et al., “Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States,” Gastroenterol., 2011, pp. 1249-1253, vol. 141.
[cited by applicant]
Chiorini, J. et al., “Cloning of Adeno-Associated Virus Type 4 (AAV4) and Generation of Recombinant AAV4 Particles,” J. Virol., Sep. 1997, pp. 6823-6833, vol. 71, No. 9.
[cited by applicant]
Chiorini, J. et al., “Cloning and Characterization of Adeno-Associated Virus Type 5,” J. Virol., Feb. 1999, pp. 1309-1319, vol. 73, No. 2.
[cited by applicant]
Chung, H. et al., “Time-restricted feeding improves insulin resistance and hepatic steatosis in a mouse model of postmenopausal obesity,” Metabolism, 2016, pp. 1743-1754, vol. 65.
[cited by applicant]
Colak, Y. et al., “SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease,” Med. Sci. Monit., 2011, pp. HY5-HY9, vol. 17, No. 5.
[cited by applicant]
Crombez, E. et al., “Hyperargininemia due to liver arginase deficiency,” Mol. Genet. Metab., Mar. 2005, pp. 243-251, vol. 84, No. 3.
[cited by applicant]
De, B. et al., “High Levels of Persistent Expression of alpha1-Antityrpsin Mediated by the Nonhuman Primate Serotype rh. 10 Adeno-associated Virus Despite Preexisting Immunity to Common Human Adeno-associated Viruses,” …
[cited by applicant]
Debosch, B. et al., “Glucose Transporter-8 (GLUT8) Mediates Glucose Intolerance and Dyslipidemia in High-Fructose Diet-Fed Male Mice,” Mol. Endocrinol., 2013, pp. 1887-1896, vol. 27.
[cited by applicant]
Debosch, B. et al., “Glucose Transporter 8 (GLUT8) Mediates Fructose-Induced de Novo Lipogenesis and Macrosteatosis,” J. Biol. Chem., Apr. 2014, pp. 10989-10998, vol. 289, No. 16.
[cited by applicant]
Debosch, B. et al., “Trehalose inhibits solute carrier 2A (SLC2A) proteins to induce autophagy and prevent hepatic steatosis,” Sci. Signal., Feb. 2016, pp. 1-13, vol. 9, No. 416, ra21.
[cited by applicant]
Dykxhoorn, D. et al., “The Silent Revolution: Rna Interference as Basic Biology, Research Tool, and Therapeutic,” Annu. Rev. Med., 2005, pp. 401-423, vol. 56.
[cited by applicant]
Elhai, J. et al., “Conjugal Transfer of DNA to Cyanobacteria,” Methods in Enzymology, 1988, pp. 747-754, vol. 167.
[cited by applicant]
Esposito, K. et al., “The metabolic syndrome and inflammation: association or causation?,” Nutr. Metab. Cardiovasc. Dis., Oct. 2004, pp. 228-232, vol. 14, No. 5.
[cited by applicant]
Felgner, P. et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,” PNAS, Nov. 1987, pp. 7413-7417, vol. 84.
[cited by applicant]
Flotte, T., “New AAV Serotypes May Broaden the Therapeutic Pipeline to Human Gene Therapy,” Mol. Ther., Jan. 2006, pp. 1-2, vol. 13, No. 1.
[cited by applicant]
Fracanzani, A. et al., “Carotid Artery Intima-media Thickness in Nonalcoholic Fatty Liver Disease,” Am. J. Med., Jan. 2008, pp. 72-78, vol. 121, No. 1.
[cited by applicant]
Gaich, G. et al., “The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes,” Cell Metab., Sep. 2013, pp. 333-340, vol. 18.
[cited by applicant]
Gao, G-P. et al., “Novel adeno-associated viruses from rhwsus monkeys as vectors for human gene therapy,” PNAS, Sep. 2002, pp. 11854-11859, vol. 99, No. 18.
[cited by applicant]
Gao, G. et al., “Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues,” J. Virol., Jun. 2004, pp. 6381-6388, vol. 78, No. 12.
[cited by applicant]
Gao, G. et al., “Biology of AAV Serotype Vectors in Liver-Directed Gene Transfer to Nonhuman Primates,” Mol. Ther., Jan. 2006, pp. 77-87, vol. 13, No. 1.
[cited by applicant]
GenBank Accession AF043303, “Adeno-associated virus 2,” complete genome, May 20, 2010; 6 pgs.
[cited by applicant]
GenBank Accession AF085716, “Adeno-associated virus 5 DNA binding trs helicase (Rep22) and capsid protein (VP1) genes,” complete cds, Feb. 9, 1999; 5 pgs.
[cited by applicant]
GenBank Accession J01901, “Adeno-associated virus 2,” complete genome, Apr. 27, 1993; 6 pgs.
[cited by applicant]
GenBank Accession U89790, “Adeno-associated virus 4,” complete genome, Aug. 21, 1997; 5 pgs.
[cited by applicant]
Ghadessy, F. et al., “Directed evolution of polymerase function by compartmentalized self-replication,” PNAS, Apr. 10, 2001, pp. 4552-4557, vol. 98, No. 8.
[cited by applicant]